Influenza Articles
The Centers for Disease Control and Prevention has issues its recommendations for use of the seasonal 2026-2027 influenza (flu) vaccines.
The U.S. Food and Drug Administration has approved mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.
A UTHealth study found adults 65 and older had a lower risk of developing Alzheimer’s disease after receiving a high-dose flu vaccine.
The Statens Serum Institut in Copenhagen found that flu vaccines may protect against heart attack and stroke, even if the flu is still developed after vaccination.
The U.S. Food and Drug Administration’s accines and Related Biological Products Advisory Committee voted to recommend approval of the Moderna’s investigational mRNA influenza vaccine, which will be marketed under the brand name mFlusiva, for the prevention of flu in adults age 50 to 64.
A study has found pediatric flu vaccines significantly reduce the number of childhood cases of influenza.
The antibody CR9114 shows promise in combating future flu pandemics as it appears to neutralize any influenza virus.
A potentially effective mucosal vaccine platform has been developed to encourage broad, protective immunity against multiple influenza virus infections.
A new study shows that influenza vaccination may help protect against heart attack and stroke even when it does not prevent people from getting the flu.
Researchers have found that adults 65 and older who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared to those who received the standard dose.
A new study demonstrates a way to stop the influenza virus from leaping from one host to the next while continuing to keep the virus from replicating inside the host.